Does long term treatment with azathioprine predispose to malignancy and death in patients with systemic lupus erythematosus? [2]

Annals of the Rheumatic Diseases

Volumn 63, Issue 3, 2004, Pages 325-326

  Nero, P ^a   Rahman, A ^b   Isenberg, D A ^b  

^a Unidade de Reumatologio   (Portugal)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE;

CANCER; CANCER MORTALITY; CANCER RISK; CONFIDENCE INTERVAL; DISEASE PREDISPOSITION; DRUG SAFETY; FOLLOW UP; HIGH RISK POPULATION; HUMAN; LETTER; LONG TERM CARE; LYMPHOMA; PATHOGENESIS; PRIORITY JOURNAL; RHEUMATIC DISEASE; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; AZATHIOPRINE; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 1342280430     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2002.005371     Document Type: Letter

References (0)